Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Furtner, J; Schöpf, V; Seystahl, K; Le Rhun, E; Rudà, R; Roelcke, U; Koeppen, S; Berghoff, A S; Marosi, C; Clement, P; Faedi, M; Watts, C; Wick, W; Soffietti, R; Weller, M; Preusser, M (2016). Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 18(3):401-407.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Wick, W; Hartmann, C; Engel, C; Stoffels, M; Felsberg, J; Stockhammer, F; Sabel, M C; Koeppen, S; Ketter, R; Meyermann, R; Rapp, M; Meisner, C; Kortmann, R D; Pietsch, T; Wiestler, O D; Ernemann, U; Bamberg, M; Reifenberger, G; von Deimling, A; Weller, M (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 27(32):5874-5880.

This list was generated on Sat Nov 18 08:30:43 2017 CET.